Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Cryptococcus neoformans Secretes Small Molecules That Inhibit IL-1 β Inflammasome-Dependent Secretion.

Tytuł:
Cryptococcus neoformans Secretes Small Molecules That Inhibit IL-1 β Inflammasome-Dependent Secretion.
Autorzy:
Bürgel PH; Laboratory of Applied Immunology, Department of Cellular Biology, Institute of Biological Sciences, University of Brasília, Brazil.; Institute of Microbiology and Infection and School of Biosciences, University of Birmingham, Edgbaston, UK B15 2TT.
Marina CL; Laboratory of Applied Immunology, Department of Cellular Biology, Institute of Biological Sciences, University of Brasília, Brazil.
Saavedra PHV; Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Albuquerque P; Laboratory of Molecular Biology of Pathogenic Fungi, University of Brasilia, Brasilia, Brazil.; Faculty of Ceilândia, University of Brasília, Brazil.
de Oliveira SAM; Laboratory of Applied Immunology, Department of Cellular Biology, Institute of Biological Sciences, University of Brasília, Brazil.
Veloso Janior PHH; Laboratory of Applied Immunology, Department of Cellular Biology, Institute of Biological Sciences, University of Brasília, Brazil.
de Castro RA; Laboratory of Applied Immunology, Department of Cellular Biology, Institute of Biological Sciences, University of Brasília, Brazil.
Heyman HM; Biological Sciences Division, Pacific Northwest National Laboratory, Richland, Washington, USA.; Bruker Daltonics Inc., Billerica, MA, USA.
Coelho C; Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.; Medical Research Council Centre for Medical Mycology, College of Medicine and Health, University of Exeter and University of Aberdeen, Aberdeen, UK.
Cordero RJB; Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Casadevall A; Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Nosanchuk JD; Departments of Medicine (Division of Infectious Diseases) and Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, USA.
Nakayasu ES; Bruker Daltonics Inc., Billerica, MA, USA.
May RC; Institute of Microbiology and Infection and School of Biosciences, University of Birmingham, Edgbaston, UK B15 2TT.
Tavares AH; Faculty of Ceilândia, University of Brasília, Brazil.
Bocca AL; Laboratory of Applied Immunology, Department of Cellular Biology, Institute of Biological Sciences, University of Brasília, Brazil.
Źródło:
Mediators of inflammation [Mediators Inflamm] 2020 Dec 03; Vol. 2020, pp. 3412763. Date of Electronic Publication: 2020 Dec 03 (Print Publication: 2020).
Typ publikacji:
Journal Article
Język:
English
Imprint Name(s):
Publication: 2005- : Sylvania, OH : Hindawi Pub. Corp.
Original Publication: Oxford, UK : Rapid Communications of Oxford Ltd., c1992-
MeSH Terms:
Cryptococcus neoformans/*metabolism
Inflammasomes/*metabolism
Interleukin-1beta/*antagonists & inhibitors
Interleukin-1beta/*metabolism
Polysaccharides/*chemistry
Animals ; Caspase 1/metabolism ; Cryptococcosis ; Culture Media, Conditioned ; Dendritic Cells/metabolism ; Fluorescent Antibody Technique ; Lactic Acid/metabolism ; Macrophages/metabolism ; Male ; Mice ; Mice, Inbred C57BL ; Phagocytosis ; Polysaccharides/metabolism ; Virulence Factors/metabolism
References:
Mol Biosyst. 2013 Jun;9(6):1522-34. (PMID: 23559334)
J Immunol. 2000 May 1;164(9):4893-8. (PMID: 10779799)
Circ Res. 2014 Oct 24;115(10):875-83. (PMID: 25185259)
Mycologia. 1980 May-Jun;72(3):578-85. (PMID: 6995832)
Front Chem. 2018 Jul 12;6:265. (PMID: 30050896)
Eukaryot Cell. 2010 Jun;9(6):835-46. (PMID: 20382758)
Eukaryot Cell. 2007 Jan;6(1):48-59. (PMID: 17114598)
Antimicrob Agents Chemother. 1991 Nov;35(11):2275-81. (PMID: 1804000)
Nature. 2009 May 21;459(7245):433-6. (PMID: 19339971)
PLoS Pathog. 2016 Dec 2;12(12):e1006035. (PMID: 27911947)
J Immunol. 1982 Oct;129(4):1675-80. (PMID: 7050244)
Infect Immun. 1999 Feb;67(2):885-90. (PMID: 9916104)
Cell Microbiol. 2014 Oct;16(10):1549-64. (PMID: 24824158)
Infect Immun. 2002 Jun;70(6):2959-64. (PMID: 12010985)
New Phytol. 2012 Oct;196(2):520-534. (PMID: 22924530)
Trends Microbiol. 2001 Jun;9(6):273-8. (PMID: 11390242)
Anal Chem. 2009 Dec 15;81(24):10038-48. (PMID: 19928838)
PLoS One. 2012;7(1):e29561. (PMID: 22253734)
Clin Microbiol Rev. 2012 Jul;25(3):387-408. (PMID: 22763631)
Trends Cell Biol. 2015 May;25(5):308-15. (PMID: 25639489)
Annu Rev Immunol. 2009;27:229-65. (PMID: 19302040)
Cell Host Microbe. 2010 Jul 22;8(1):7-11. (PMID: 20638636)
J Immunol. 1989 Jan 15;142(2):659-65. (PMID: 2521352)
Curr Biol. 2006 Nov 7;16(21):2156-60. (PMID: 17084701)
Front Biosci. 1997 Nov 01;2:e99-107. (PMID: 9342305)
Anal Chem. 2009 May 1;81(9):3429-39. (PMID: 19358599)
Nat Rev Microbiol. 2011 Mar;9(3):193-203. (PMID: 21326274)
Curr Biol. 2006 Nov 7;16(21):2161-5. (PMID: 17084702)
J Immunol. 2011 Sep 1;187(5):2748-54. (PMID: 21804020)
Nat Rev Microbiol. 2005 Oct;3(10):753-64. (PMID: 16132036)
Eur J Immunol. 2011 Aug;41(8):2260-8. (PMID: 21681738)
J Chromatogr. 1992 May 8;576(2):334-9. (PMID: 1400722)
Antimicrob Agents Chemother. 1998 Jun;42(6):1437-46. (PMID: 9624491)
Nat Med. 2015 Mar;21(3):248-55. (PMID: 25686105)
mBio. 2011 Jun 07;2(3):e00103-11. (PMID: 21652778)
PLoS One. 2011;6(10):e26232. (PMID: 22039448)
Infect Immun. 2014 Feb;82(2):882-92. (PMID: 24478101)
Cell Host Microbe. 2009 May 8;5(5):487-97. (PMID: 19454352)
J Biol Chem. 2006 Jan 27;281(4):1868-75. (PMID: 16278213)
Immunity. 2018 Jan 16;48(1):35-44.e6. (PMID: 29195811)
Nat Rev Microbiol. 2009 Feb;7(2):99-109. (PMID: 19148178)
J Immunol. 2005 Mar 15;174(6):3461-8. (PMID: 15749881)
J Infect Dis. 2005 Jan 1;191(1):127-37. (PMID: 15593014)
Rev Iberoam Micol. 1997 Jun;14(2):42-3. (PMID: 16854168)
J Immunol. 2015 Nov 15;195(10):4962-72. (PMID: 26466953)
mBio. 2011 Aug 09;2(4):. (PMID: 21828220)
Cell Host Microbe. 2010 May 20;7(5):376-87. (PMID: 20478539)
Biophys J. 2009 Aug 19;97(4):937-45. (PMID: 19686640)
Cell Microbiol. 2015 May;17(5):702-13. (PMID: 25394938)
Eukaryot Cell. 2007 Aug;6(8):1400-10. (PMID: 17573547)
Front Immunol. 2018 Jan 19;8:1987. (PMID: 29403476)
PLoS Pathog. 2016 Sep 01;12(9):e1005849. (PMID: 27583447)
Eukaryot Cell. 2008 Jan;7(1):58-67. (PMID: 18039940)
Eukaryot Cell. 2005 Feb;4(2):465-75. (PMID: 15701808)
FEMS Yeast Res. 2006 Jun;6(4):537-42. (PMID: 16696649)
Sci Adv. 2017 Aug 16;3(8):e1700898. (PMID: 28835924)
Infect Immun. 2007 Oct;75(10):4792-8. (PMID: 17664261)
PLoS One. 2016 Oct 3;11(10):e0163919. (PMID: 27695080)
Infect Immun. 2017 Jan 26;85(2):. (PMID: 27872238)
Cell Microbiol. 2006 Nov;8(11):1812-25. (PMID: 16824040)
Immunol Rev. 2015 May;265(1):130-42. (PMID: 25879289)
Adv Appl Microbiol. 2009;68:133-216. (PMID: 19426855)
Autoimmun Rev. 2018 Jul;17(7):694-702. (PMID: 29729449)
Cold Spring Harb Perspect Med. 2014 Nov 10;5(7):a019661. (PMID: 25384769)
PLoS Pathog. 2014 Nov 06;10(11):e1004462. (PMID: 25375146)
Infect Immun. 2010 Apr;78(4):1601-9. (PMID: 20145096)
Cell Res. 2013 Jul;23(7):965-8. (PMID: 23567555)
Front Microbiol. 2016 Feb 09;7:105. (PMID: 26903984)
Future Microbiol. 2013 Sep;8(9):1107-16. (PMID: 24020739)
Cell Rep. 2014 Aug 21;8(4):974-82. (PMID: 25127135)
Infect Genet Evol. 2009 Jul;9(4):401-16. (PMID: 19460306)
Immunity. 2013 Aug 22;39(2):372-85. (PMID: 23973224)
Front Immunol. 2017 Nov 20;8:1572. (PMID: 29209318)
mBio. 2018 Aug 21;9(4):. (PMID: 30131363)
Clin Microbiol Rev. 1995 Oct;8(4):515-48. (PMID: 8665468)
Rev Inst Med Trop Sao Paulo. 2013 Nov-Dec;55(6):371-6. (PMID: 24213188)
J Pharmacol Exp Ther. 2001 Oct;299(1):187-97. (PMID: 11561079)
PLoS Pathog. 2015 Jul 23;11(7):e1004948. (PMID: 26204108)
Med Mycol. 2000 Oct;38(5):379-83. (PMID: 11092385)
Nat Commun. 2018 Oct 15;9(1):4260. (PMID: 30323213)
Eukaryot Cell. 2014 Feb;13(2):329-40. (PMID: 24376002)
Lancet Infect Dis. 2017 Aug;17(8):873-881. (PMID: 28483415)
Cell Rep. 2015 Jun 16;11(10):1535-48. (PMID: 26027935)
J Immunol. 2017 May 1;198(9):3558-3564. (PMID: 28298525)
J Immunol. 2015 Mar 1;194(5):2219-31. (PMID: 25637026)
PLoS One. 2010 Apr 02;5(4):e10008. (PMID: 20368800)
mBio. 2013 Dec 31;5(1):e00986-13. (PMID: 24381301)
Curr Opin Microbiol. 2016 Dec;34:67-74. (PMID: 27522351)
Annu Rev Microbiol. 2006;60:69-105. (PMID: 16704346)
Infect Immun. 1995 Aug;63(8):2919-23. (PMID: 7622213)
J Leukoc Biol. 2003 Sep;74(3):370-8. (PMID: 12949240)
J Leukoc Biol. 2011 Aug;90(2):357-66. (PMID: 21531876)
Microbes Infect. 2014 Oct;16(10):845-54. (PMID: 25193031)
Mol Microbiol. 2008 Sep;69(6):1456-75. (PMID: 18673460)
Proc Natl Acad Sci U S A. 2009 Jan 27;106(4):1228-33. (PMID: 19164571)
Eukaryot Cell. 2015 Dec;14(12):1173-85. (PMID: 26453651)
PLoS Negl Trop Dis. 2013 Dec 05;7(12):e2595. (PMID: 24340123)
AIDS. 2009 Feb 20;23(4):525-30. (PMID: 19182676)
Fungal Genet Biol. 2012 Sep;49(9):677-8. (PMID: 22326419)
Nucleic Acids Res. 2015 Jul 1;43(W1):W251-7. (PMID: 25897128)
Grant Information:
P30 CA008748 United States CA NCI NIH HHS; R01 HL059842 United States HL NHLBI NIH HHS
Substance Nomenclature:
0 (Culture Media, Conditioned)
0 (IL1B protein, mouse)
0 (Inflammasomes)
0 (Interleukin-1beta)
0 (Polysaccharides)
0 (Virulence Factors)
33X04XA5AT (Lactic Acid)
EC 3.4.22.36 (Casp1 protein, mouse)
EC 3.4.22.36 (Caspase 1)
Entry Date(s):
Date Created: 20201231 Date Completed: 20210921 Latest Revision: 20230121
Update Code:
20230123
PubMed Central ID:
PMC7748918
DOI:
10.1155/2020/3412763
PMID:
33380899
Czasopismo naukowe
Cryptococcus neoformans is an encapsulated yeast that causes disease mainly in immunosuppressed hosts. It is considered a facultative intracellular pathogen because of its capacity to survive and replicate inside phagocytes, especially macrophages. This ability is heavily dependent on various virulence factors, particularly the glucuronoxylomannan (GXM) component of the polysaccharide capsule. Inflammasome activation in phagocytes is usually protective against fungal infections, including cryptococcosis. Nevertheless, recognition of C. neoformans by inflammasome receptors requires specific changes in morphology or the opsonization of the yeast, impairing proper inflammasome function. In this context, we analyzed the impact of molecules secreted by C. neoformans B3501 strain and its acapsular mutant Δcap67 in inflammasome activation in an in vitro model. Our results showed that conditioned media derived from B3501 was capable of inhibiting inflammasome-dependent events (i.e., IL-1 β secretion and LDH release via pyroptosis) more strongly than conditioned media from Δcap67 , regardless of GXM presence. We also demonstrated that macrophages treated with conditioned media were less responsive against infection with the virulent strain H99, exhibiting lower rates of phagocytosis, increased fungal burdens, and enhanced vomocytosis. Moreover, we showed that the aromatic metabolite DL-Indole-3-lactic acid (ILA) and DL-p-Hydroxyphenyllactic acid (HPLA) were present in B3501's conditioned media and that ILA alone or with HPLA is involved in the regulation of inflammasome activation by C. neoformans . These results were confirmed by in vivo experiments, where exposure to conditioned media led to higher fungal burdens in Acanthamoeba castellanii culture as well as in higher fungal loads in the lungs of infected mice. Overall, the results presented show that conditioned media from a wild-type strain can inhibit a vital recognition pathway and subsequent fungicidal functions of macrophages, contributing to fungal survival in vitro and in vivo and suggesting that secretion of aromatic metabolites, such as ILA, during cryptococcal infections fundamentally impacts pathogenesis.
Competing Interests: The authors declare that there is no conflict of interest regarding the publication of this paper.
(Copyright © 2020 Pedro Henrique Bürgel et al.)
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies